YOLFTbeta
Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA · NASDAQ · Healthcare / Biotechnology

105.35USD+0.36 (+0.34%)

Price History

Full chart

Market Stats

Previous Close104.99
Open104.28
Day Range101.56 – 106.87
52-Week Range25.23 – 115.52
Volume679.70K
Market Cap5.31B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.07
Dividend Yield0.00%
Beta-0.11
50-Day Avg89.99
200-Day Avg67.60

About

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Lawrence Otto Klein Ph.D.
  • Employees68
  • Headquarters855 Oak Grove Avenue, Menlo Park, CA, United States, 94025, USA
  • Websitehttps://orukatx.com

Leadership

  • Dr. Lawrence Otto Klein Ph.D.President, CEO & Director · b. 1983
  • Mr. Paul T. QuinlanGeneral Counsel & Secretary · b. 1963
  • Dr. Joana Goncalves M.D.Chief Medical Officer · b. 1974
  • Mr. Arjun Agarwal CPASenior VP of Finance & Treasurer · b. 1976
  • Ms. Laura SandlerChief Operating Officer · b. 1977
  • Mr. Alan LadaVP of IR & Capital Markets
  • Mr. Christopher FinchSenior VP and Head of Business Development & Strategy
  • Dr. Rajiv PanwarSenior VP and Head of Chemistry, Manufacturing & Controls
  • Mr. Larry Todd EdwardsChief Commercial Officer · b. 1963

Financials

Income Statement

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue545.00K3.89M46.86M-----------------0
Growth (%)-+613.39%+1105.27%------------------
Cost of Revenue57.78M3.18M2.34M--338.00K2.92M43.00K26.00K12.00K19.00K24.00K27.00K22.00K89.00K93.00K91.00K114.00K111.00K27.00K83.00K
Gross Profit-57.23M706.00K44.52M---338.00K-2.92M-43.00K-26.00K-12.00K-19.00K-24.00K-27.00K-22.00K-89.00K-93.00K-91.00K-114.00K-111.00K-27.00K-83.00K
Gross Margin-10501.47%18.16%95.00%------------------
Operating Expense15.80M141.28M61.07M--8.84M4.44M4.28M6.91M9.68M11.44M16.59M18.68M8.10M5.72M9.67M19.24M9.73M7.18M88.10M121.97M
Operating Income-73.04M-140.57M-16.55M-19.49M-22.85M-9.18M-7.36M-4.32M-6.94M-9.69M-11.46M-16.61M-18.71M-8.12M-5.81M-9.77M-19.34M-9.84M-7.30M-88.12M-122.05M
Operating Margin-13401.47%-3615.59%-35.33%------------------
EBITDA-67.67M-129.01M-9.86M-19.03M-10.78M-8.07M-4.76M-4.27M-6.91M-9.68M-11.43M-16.42M-18.52M-7.94M-5.55M-9.64M-19.23M-9.81M-5.23M-82.23M-105.35M
EBITDA Margin-12415.78%-3318.08%-21.03%------------------
Net Income-71.61M-132.78M-12.30M-19.43M-9.14M-8.42M-5.36M-4.32M-6.94M-9.69M-11.45M-16.44M-18.49M-7.93M-5.48M-9.74M-19.32M-9.93M-5.34M-83.72M-105.43M
Net Income Margin-13139.63%-3415.05%-26.25%------------------
R&D-89.37M42.65M11.03M10.01M3.11M-1.09M2.93M5.63M7.06M12.35M14.08M4.24M1.83M4.99M13.83M4.46M1.01M75.06M100.64M
R&D as % of Total Revenue-2298.61%91.02%------------------
Interest Expense1.00M588.00K103.00K178.00K185.00K8.00K5.00K3.00K------7.00K9.00K---1.47M0
Interest Expense % of Total Revenue184.22%15.12%0.22%------------------

Balance Sheet

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets108.05M184.41M120.68M11.08M9.37M8.16M6.50M3.21M17.08M16.13M39.57M24.63M12.37M6.83M8.54M50.43M54.92M43.09M37.86M396.02M488.62M
Total Liabilities51.28M114.56M53.02M16.39M1.96M1.39M770.00K305.00K1.50M1.39M1.50M2.44M2.09M793.00K926.00K3.91M3.88M1.41M841.00K13.80M16.69M
Total Equity56.76M69.84M67.66M-5.31M7.41M6.77M5.73M2.91M15.58M14.74M38.07M22.19M10.28M6.03M7.61M46.52M51.04M41.67M37.02M382.22M471.93M
Cash37.76M60.34M32.06M7.74M7.76M7.03M5.94M2.92M16.76M15.35M38.80M7.40M8.70M6.61M8.36M49.07M53.36M42.45M37.43M61.58M46.94M
Total Debt12.07M22.73M-12.30M----------25.00K450.00K483.00K383.00K280.00K968.00K1.93M
Net Debt-25.69M-37.61M-32.06M4.56M-7.76M-7.03M-5.94M-2.92M-16.76M-15.35M-38.80M-7.40M-8.70M-6.61M-8.34M-48.62M-52.88M-42.06M-37.15M-60.61M-45.00M

Cash Flow

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312024-12-312025-12-31
Operating Cash Flow-59.03M-37.06M-45.96M-18.40M-41.73M-8.32M-6.96M-4.08M-5.29M-9.41M-10.53M-14.99M-17.47M-8.24M-4.80M-7.72M-18.76M-10.91M-57.84M-88.21M
Investing Cash Flow-1.18M-62.06M21.09M-2.52M45.63M265.00K2.01M--32.00K-19.00K-11.00K-16.41M12.93M3.05M-4.00K-19.00K-43.00K-2.00K-330.13M-96.75M
Financing Cash Flow81.16M121.69M-3.40M12.80M-3.89M7.32M3.87M1.05M19.16M8.02M33.99M-5.85M3.10M6.56M48.45M23.09M-449.54M170.31M
Capital Expenditure2.57M2.44M381.00K1.34M185.00K4.00K19.00K032.00K19.00K11.00K12.00K3.00K4.00K4.00K19.00K43.00K2.00K189.00K209.00K
Free Cash Flow-61.60M-39.50M-46.34M-19.75M-41.91M-8.33M-6.98M-4.08M-5.32M-9.43M-10.54M-15.00M-17.48M-8.25M-4.80M-7.74M-18.80M-10.91M-58.03M-88.42M
FCF to OCF104.35%106.59%100.83%107.30%100.44%100.05%100.27%100.00%100.61%100.20%100.10%100.08%100.02%100.05%100.08%100.25%100.23%100.02%100.33%100.24%

Earnings

Report DateDec 31, 2000Mar 31, 2001Jun 30, 2001Oct 25, 2001Feb 6, 2002Apr 25, 2002Jul 25, 2002Oct 24, 2002May 1, 2003Jul 31, 2003Oct 30, 2003Feb 5, 2004May 6, 2004Aug 9, 2004Nov 9, 2004Feb 15, 2005May 2, 2005Aug 4, 2005Nov 1, 2005Feb 27, 2006May 5, 2006Aug 3, 2006Nov 2, 2006Feb 27, 2007May 9, 2007Aug 2, 2007Nov 2, 2007Feb 28, 2008May 9, 2008Jul 24, 2008Oct 31, 2008Feb 26, 2009May 8, 2009Aug 11, 2009Oct 30, 2009Feb 25, 2010May 11, 2010Aug 10, 2010Oct 29, 2010Mar 3, 2011May 10, 2011Aug 9, 2011Oct 28, 2011Mar 1, 2012May 8, 2012Aug 7, 2012Nov 2, 2012Feb 28, 2013May 14, 2013Aug 14, 2013Nov 13, 2013Mar 21, 2014May 14, 2014Aug 14, 2014Nov 13, 2014Mar 20, 2015May 13, 2015Aug 12, 2015Nov 13, 2015Mar 18, 2016May 12, 2016Aug 10, 2016Nov 15, 2016Mar 22, 2017May 15, 2017Aug 15, 2017Nov 10, 2017Mar 23, 2018May 9, 2018Aug 9, 2018Nov 14, 2018Feb 27, 2019May 8, 2019Aug 1, 2019Nov 6, 2019Feb 18, 2020May 6, 2020Aug 5, 2020Nov 2, 2020Mar 18, 2021May 11, 2021Aug 4, 2021Nov 2, 2021Mar 14, 2022May 2, 2022Aug 2, 2022Oct 28, 2022Feb 24, 2023Apr 24, 2023Jul 21, 2023Nov 7, 2023Feb 1, 2024Apr 25, 2024Aug 27, 2024Nov 13, 2024Mar 6, 2025May 14, 2025Aug 11, 2025Nov 12, 2025Mar 13, 2026May 13, 2026Aug 10, 2026Nov 11, 2026
EPS Estimate----------------------------------------------------------------------0.22-0.19-0.14-1.98-1.86-1.30-0.99-2.04-2.58-2.51-2.44-1.87-2.37-2.30-2.24-----------0.32-0.41-0.44-0.43-0.52-0.62-0.54-0.49-0.68
EPS Actual-266716.81-264612.63-298456.93-322130.85-332035.15-551064.05-199119.22-34523.57-148954.35-140568.66-92820.59-67591.86-117100.37-62396.69-61629.16-70271.54-70080.96-73423.04-79434.60-90821.46-72894.27-66146.83-93011.46-223861.08-52297.0598771.87-48820.59-39536.99-1000000.00-984225.19-1000000.00-1000000.0011586.09-10297.06-5158.52-7912.70-2907.85-2358.16-2166.71-1701.07-2265.30260.21-1574.29-1473.10-1049.15-854.53-613.74-571.20-533.60-986.26-240.50-283.98-192.29-173.08-164.22-186.65-196.00-148.61-67.28-75.60-87.01-92.78-110.97-100.93-103.03-127.91-83.24-76.99-43.37-2.70-1.98-1.98-1.86-1.14-0.76-0.39-0.83-0.73-0.33-0.55-0.33-0.34-0.33-0.55-0.55-0.22-0.16-0.08-0.09-1.23-1.19-0.90-0.14-2.22-1.46-0.54-0.40-0.46-0.55-0.45-0.48-0.55-
Surprise----------------------------------------------------------------------1127.27%-942.11%-1314.29%6.06%38.71%41.54%60.61%59.31%71.71%86.85%77.46%82.35%85.65%85.65%75.45%-----------356.25%-31.71%9.09%-6.98%-5.77%26.90%11.11%-12.24%-
Timing---------------------------------------------------------------------------------------------Pre-marketAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap5.31B
Enterprise Value604.86M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.36
EPS-2.07
Book Value18.20
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-154.94M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-18.23%
Return on Assets-12.95%
Shares Outstanding66.21M
Shares Float56.89M
Beta-0.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 13 analystsTarget 155.00
  • Strong Buy
    11
  • Buy
    2

Ownership Breakdown

Institutions
116.93%
Insiders
1.26%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    9.06M13.68%
  • BlackRock Inc
    4.99M7.54%
  • VR Adviser, LLC
    4.15M6.27%
  • Fairmount Funds Management LLC
    3.71M5.60%
  • Capital World Investors
    3.40M5.14%
  • RTW INVESTMENTS, LLC
    3.14M4.74%
  • State Street Corp
    2.67M4.04%
  • Vanguard Capital Management, LLC
    2.36M3.57%
  • Paradigm Biocapital Advisors LP
    2.14M3.24%
  • Deep Track Capital, LP
    1.93M2.91%
  • Bellevue Group AG
    1.66M2.50%
  • Franklin Templeton Inc
    1.62M2.45%
  • Remedium Capital Partners, LLC
    1.57M2.36%
  • RA Capital Management, LLC
    1.55M2.35%
  • Viking Global Investors LP
    1.50M2.27%
  • Geode Capital Management, LLC
    1.43M2.16%
  • Jupiter Topco LLC
    1.38M2.08%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.90M2.87%
  • State Street® SPDR® S&P® Biotech ETF
    1.63M2.46%
  • American Funds SMALLCAP World A
    1.53M2.31%

Dividends

20241×
19.36Aug 29, 2024

Stock Splits

  • Sep 3, 20241:12
  • Apr 4, 20191:18
  • Sep 4, 20151:7
  • Mar 5, 20131:6
  • Jan 28, 20091:20
  • Feb 23, 20041:3